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Objectives: The aim of this study was to determine the long-term effects of a moderate protein diet
(MPD) on renal function, low-grade inﬂammation, and oxidative stress in older adults with type 2
diabetes, which to date are unclear.
Methods: Seventy-four older adults with type 2 diabetes and chronic kidney disease (stage G3b–
G4) were enrolled in the study. During the 4-wk baseline period (T0), all patients were asked to
follow a normal protein diet regimen, providing 1.1 g/kg daily. Successively, all patients were asked
to follow an MPD, for 36 mo, providing 0.7 g/kg daily, for only 6 d/wk. Patients who refused to
follow an MPD treatment were included in the control (NPD [normal protein diet] group). During
the 36 mo of the study, creatinine clearance, blood urea nitrogen, proteinuria, blood pressure,
glycated hemoglobin (Hb)A1c, fat-free mass, low-grade inﬂammation (interleukin-6 and C-reactive
protein) were evaluated monthly and oxidative stress (urinary 8-epiprostaglandin [Epi-PG]F2a)
was evaluated every 3 mo.
Results: During T0, mean creatinine clearance, proteinuria, blood urea nitrogen, blood pressure,
HbA1c, fat free mass, low-grade inﬂammation, and oxidative stress were similar in both groups.
After 36 mo, a signiﬁcant reduction in decline of renal function was observed in the MPD group but
not in controls (2.4  0.2 versus 5.7  0.5 mL$min$y, respectively; P < 0.05 versus control).
Similarly, a signiﬁcant reduction in proteinuria, serum interleukin-6, serum C-reactive protein, and
urinary 8-Epi-PGF2a excretion, was observed in the MPD group (P < 0.05 versus NPD).
Conclusion: In older adults with type 2 diabetes, long-term effects of an MPD regimen are asso-
ciated with a signiﬁcant decline of renal function, proteinuria, low-grade inﬂammation, and
oxidative stress without a change in fat-free mass.
 2014 Elsevier Inc. All rights reserved.Introduction
Experimental animal models have demonstrated the beneﬁ-
cial effects of dietary protein restriction in delaying the pro-
gression of renal disease [1]. In fact, dietary protein restriction
may retard the decline of renal function and alleviates uremic
symptoms caused by the accumulation of phosphorus, sulphates,
organic acids, and urea [2,3]. It has been suggested that dietary
protein restriction also may delay the need for dialysis therapyrdano).
ll rights reserved.[4], and favors the correction of secondary hyperparathyroidism
and metabolic acidosis [5]. However, data on dietary protein
restriction are unclear. In a recent study with 112 patients with
type 2 diabetes mellitus (T2DM) and overt nephropathy, it was
reported that protein restriction was neither feasible nor efﬁca-
cious. The authors reported that the prescribed protein intake in
the low-protein diet group was not statistically different from
the protein intake in the normal protein diet group. Thus,
non-adherence to the prescribed dietary protein restriction may
result in an underestimation of its beneﬁcial effects, in this study
[6]. In fact, adherence to dietary protein restriction also could
affect depressive symptoms. We previously demonstrated that
Table 1
Baseline clinical characteristics of patients in NPD and MPD groups
NPD group
(n ¼ 34)
MPD group
(n ¼ 40)
Age (y) 71  2 72  3
BMI (kg/m2) 31.4  2 30.8  3
SBP (mm Hg) 135  3 136  4
DBP (mm Hg) 81  2 80  2
FPG (mg/dL) 124  8 127  9
HbA1c (%) 6.7  0.3 6.6  0.4
Serum albumin (g/dL) 3.6  0.2 3.5  0.3
Serum creatinine (mg/dL) 2.0  0.2 2.1  0.2
Serum BUN (mg/dL) 40.4  4 40.1  3
FFM (%) 59  2 58  3
CRP (mg/L) 4.8  0.5 4.9  0.4
IL-6 (pg/mL) 5.6  0.9 5.5  0.9
8-epi-PGF2a (pmol/mmol Cr) 188  39 201  45
Urinary protein excretion (g/d) 2.3  0.9 2.4  0.5
CrCl (mL$min$1.73 m2) 35.2  0.5 33.8  0.7
BMI, body mass index; BUN, blood urea nitrogen; CrCl, creatinine clearance; CRP,
C-reactive protein; DBP, diastolic blood pressure; 8-epi-PGF2a, 8-epi-prosta-
glandin F2a; FFM, fat-free mass; FPG, fasting plasma glucose; HbA1c, glycated
hemoglobin; IL, interleukin; MPD, moderate protein diet; NPD, normal protein
diet; SBP, systolic blood pressure
Values are mean  SEM
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6 d/wk was associated with an improvement in depressive
symptoms and health-related quality of life in older patients
with T2DM [7]. Furthermore, it has been reported that a reduced
protein intake has an antioxidant effect in chronic kidney disease
(CKD) in animals and humans [8,9]. In an animal study, dietary
protein restriction appeared to ameliorate inﬂammation, sup-
press oxidative stress, and reduce proteinuria [10]. Additionally it
has been reported that unsaturated lipids also might be linked to
anti-inﬂammatory status [11]. In this regard, little data are
available on the long-term effects of a moderate protein diet
(MPD) restriction regimen in older adults. Thus, in this study, we
evaluated the effects of an MPD regimen, after 36 mo, on the
decline of renal function, low-grade inﬂammation, oxidative
stress, proteinuria, and body composition in older patients with
T2DM and CKD.
Methods
Patient population
In the study protocol, 74 older patients with T2DM participated. All patients
were clinically assessed with a medical history, physical examination, and
routine laboratory tests. Eligibility criteria for all patients included age >65 y;
CKD (stage G3b–G4 deﬁned according to the Kidney Disease: Improving Global
Outcomes classiﬁcation) [12] and T2DM (deﬁned according to American Diabetes
Association) [13] for at least 15 y and treated by diet plus insulin injection. All
participants had arterial hypertension (deﬁned according to Eighth Joint National
Committee criteria) [14] and were being treated by diet plus oral Ras inhibitors.
During the 4-wk baseline period (T0), all patients were requested to follow a
normal protein diet regimen, providing 1.1 g/kg daily. Successively, all patients
were asked to follow a restricted MPD for 36 mo, providing 0.7 g/kg daily, for 6 d/
wk. Forty patients agreed to follow an MPD regimen (18 men; body mass index
[BMI] 30.8  3 kg/m2; age 72  3 y). Thirty-four patients (16 men; BMI
31.4  2 kg/m2; age 71  2 y) refused to adhere to an MPD regimen and were
included in the normal protein diet (NPD) group. Patient characteristics are re-
ported in Table 1. The purpose of the study was explained to all patients and their
voluntary written consent was obtained before starting. The study protocol was
reviewed and approved by the Ethics Committee of our Institution (protocol N.
150114/514).
Experimental protocol
All patients were instructed to consume aweightmaintenance diet providing
about 27 to 30 kcal/kg daily and containing about 250 to 300 g of carbohydrates.
During the 4-wk baseline period (T0), patients followed a normal protein intake
regimen; dietary carbohydrates and lipids represented 50% and 25% of the total
caloric intake. In theMPD group, lipid contribution to total calories was increased
to 35% (increasing the unsaturated fat portion), phosphate and calcium intake
were 872  63 mg and 743  79 mg, respectively. In the MPD group, more than
65% of the ingested protein was of high biological value. One day per week
(usually on Sunday) patients were off their diet. At baseline, all patients were
visitedweekly. During the 36mo of follow-up, both groups were visitedmonthly.
To verify compliance with the diet, patients in the MPD group were asked to
return to the clinical unit on a monthly basis for a 2-d dietary recording [15].
All participants were given instructions for 24-h urine samples, recording
volume and time of collection at each visit. At each visit, two consecutive 24-h
urine specimens were collected from the patients on the same day of the
weighed dietary record to determine endogenous creatinine clearance (CrCl),
urinary protein, and nitrogen excretion. CrCls were estimated using the Chronic
Kidney Disease Epidemiology Collaboration formulas and expressed in
mL$min$1.73 m2 of surface area [16]. The 24-h urinary nitrogen output was
considered the standard criteria for protein intake evaluation [15]. Urinary pro-
tein excretion was measured from 24-h urine samples using a modiﬁcation of
Coomassie Brilliant Blue method (Total Protein Test Kit, Bio-Rad Laboratories srl,
Milan, Italy) [17]. Serum samples for interleukin (IL)-6 and C-reactive protein
(CRP) were evaluated and done in duplicate using commercially available
immunosorbent kits (human IL-6 enzyme-linked immunosorbent assay, Diac-
lone, France and CRP Ultra ABBOTT Diagnostics, Abbott Park, IL, USA). Food intake
was analyzed by Dietosystem (DS Medica srl, 20125 Milano, Italy). Body
composition was assessed with a multifrequency bioelectrical impedance meter
using a Dietosystem Human IM Plus. Brieﬂy, whole-body resistance and reac-
tance were measured with four surface electrodes placed on the right wrist and
ankle. An electrical current at the following frequencies: 1, 5, 10, 50 and 100 kHzwas produced by a generator (Dietosystem Human IM Plus) and applied to the
skin with adhesive electrodes (Mod. EL01 PG-500 28  34 mm), with the indi-
vidual lying supine [18].
In all participants, urinary concentration of 8-isoprostane (iso)-prostaglandin
(PG) F2a was determined at baseline and every 3 mo thereafter, by enzyme
immunoassay for the quantitative determination 8-isoprostane (IBL Immuno-
Biological Laboratories Hamburg, Germany). All samples were free of organic
solvents before assay. Samples were assayed immediately after collection. Sam-
ples that could not be assayed immediately were stored at80C in the presence
of 0.005% butylated hydroxytoluene to prevent oxidative formation of
isoprostane. All samples were evaluated within 72 h. Urine samples were
centrifuged brieﬂy to remove sediment and proceed with the puriﬁcation using
the 8-isoprostane Afﬁnity Puriﬁcation Kit (DDT 58 Cod 516358, Italy Cabrus.a.s).
Urine samples give an excellent correlation to gas chromatography-mass spec-
trometry after puriﬁed by solid-phase extraction and thin-layer chromatography
before analyzed. Urinary concentrations of 8-iso-PGF2a (pmol/L) were corrected
by urinary creatinine concentration (mmol/L) to account for differences in renal
excretory function [19].
Statistical analysis
All data are expressed as mean  SE. The data were analyzed by analysis of
variance for repeated measures. Comparison between the two groups of pa-
tients was performed by unpaired t test. Comparison in the same group before
and after of the treatments (T0 versus T36), were performed by paired t test.
Differences at the P < 0.05 level of probability were considered signiﬁcant.
Statistical analysis was performed using SPSS software package (version 16.0,
SPSS Inc, Chicago, IL, USA).
Results
At baseline (T0), BMI, fat-free mass (FFM,) systolic blood
pressure (SBP), diastolic blood pressure (DBP), glycated hemo-
globin (Hb)A1c, serum creatinine, blood urea nitrogen (BUN), and
urinary protein excretion were similar in both study groups and
are reported in Table 1.
Renal function and blood pressure
After 36mo, serumcreatinine levels in theNPDgroup increased
from2.0 0.2mg/dLatbaseline to3.90.3mg/dLatT36(P<0.01);
CrCl decreased from 35.2  0.5 mL$min$1.73 m2 at baseline to
18.1  0.3 mL$min$1.73 m2 at 36 mo (P < 0.01). During the same
time period, BUN increased from 40.4 4mg/dL to 86.5 2mg/dL
(P < 0.01). Mean urinary protein excretion increased from
2.3  0.9 g/d but did not change after T36 (2.4  0.8 g/d; P ¼ ns).
Fig. 1. Changes in (A) creatinine clearance and (B) 24-h proteinuria in older patients
with diabetes on a moderate protein diet (MPD) (white) or normal protein diet
(NPD) (black). *P < 0.05 versus NPD.
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from 2.1  0.2 mg/dL at T0 to 2.8  0.6 mg/dL at T36 (P < 0.05);
CrCl decreased from 33.8  0.7 mL$min$1.73 m2 at T0 to
26.6  0.4 mL$min$1.73 m2 at T36 (P < 0.05); and serum BUN
increased from 40.1  3 mg/dL at T0 to 50.2  4 mg/dL at T36
(P < 0.05). Mean urinary protein excretion signiﬁcantly
decreased from 2.4  0.5 g/d at T0 to 1.1  0.2 g/d at T36
(P < 0.05).
After 36 mo, an annual decline was observed in CrCl of
5.7 0.5 mL/min in NPD group, while it was signiﬁcantly reduced
to 2.4  0.2 mL/min in the MPD group (P < 0.05 versus NPD).
In the NPD group, SBP and DBP at T0 were 135  3 and
81  2 mm Hg, respectively and did not change at T36 (137  2
and 78  2 mm Hg, respectively; P ¼ ns).
In the MPD group, SBP and DBP at T0 were 136  4 and
80  2 mm Hg, respectively and did not change at T36 (135  3
and 79  2 mm Hg, respectively; P ¼ ns). (See Fig. 1).
Nutritional parameters
In the NPD group, daily mean protein intake at T0 was
1.13 0.2 g/kg and did not change during the 36mo of treatment
(i.e., at T36 it was 1.08  0.2 g/kg; P ¼ ns). At T0, BMI was
31.4  2 kg/m2 and did not change at T36 (32.2  1.0 kg/m2;
P ¼ ns). FFM at T0 was 59.3%  2% and did not change at T36
(58.2% 3%; P¼ ns). At T0, serum albuminwas 3.6 0.2 g/dL and
did not change at T36 (3.4  0.2 g/dL; P ¼ ns). At T0, fasting
plasma glucose was 124  8 mg/dL and did not change at T36
(128 7 mg/dL; P¼ ns). HbA1c at T0 was 6.7% 0.3% and did not
change at T36 (6.8%  0.1%; P ¼ ns).
In the MPD group, daily mean protein intake at T0 was
1.15 0.2 g/kg and was signiﬁcantly reduced during the 36mo of
treatment; at T36 it was 0.76 0.1 g/kg (P< 0.05 versus T0). BMI
at T0was 30.8 3 kg/m2 and did not change at T36 (31.51.1 kg/
m2; P¼ ns); . FFM at T0was 58.7% 3% and did not change at T36
(57.5% 4%; P¼ ns). Serum albumin at T0 was 3.5 0.3 g/dL and
did not change at T36 (3.4  0.3 g/dL; P ¼ ns). Fasting plasma
glucose at T0 was 127  9 mg/dL and did not change at T36
(126 8mg/dL; P¼ ns); HbA1c at T0 was 6.6% 0.4% and did not
change at T36 (6.5%  0.2%; P ¼ ns).
Low-grade inﬂammation and oxidative stress
In the NPD group, CRP levels at T0 were 4.8  0.5 mg/L and
did not change at T36 (4.6  0.5 mg/L; P ¼ ns). IL-6 levels at T0
were 5.6  0.9 pg/mL and did not change at T36 (5.8  0.8 mg/L;
P ¼ ns).
In the MPD group, CRP levels were reduced from
4.9 0.4 mg/L at T0 to 2.8 0.4 mg/L at T36 (P< 0.05). Similarly,
IL-6 levels were reduced from 5.5  0.9 pg/mL at T0 to 4.2  0.7
pg/mL at T36 (P < 0.05).
In the NPD group, urinary 8-Epi-PGF2a excretions at T0 were
188  39 pmol/mmol of creatinine and did not change signiﬁ-
cantly at T36 (197  43 pmol/mmol of creatinine; P ¼ ns). In the
MPD group, urinary 8-Epi-PGF2a excretions were reduced from
201  45 pmol/mmol of creatinine at T0 to 115  29 pmol/mmol
of creatinine at T36 (P < 0.05). A positive correlation was
observed between protein intake and urinary 8-iso-PGF2a
excretion (r ¼ 0.70; P < 0.01). (See Figs. 2 and 3.)
Discussion
In this study, we reported that, an MPD regimen (6 d/wk) in
older patients with T2DM signiﬁcantly reduced renal failure by42% (5.7 versus 2.4 mL/min annually; P < 0.001). This beneﬁcial
effect is also associated with an improvement in low-grade
inﬂammation, oxidative stress, and proteinuria. Additionally, the
MPD did not affect either glycemic control or nutritional status,
demonstrating its sustainability long-term.
The role of an MPD regimen in older adults is not clear. Di-
etary protein restriction has been proposed for many years to
delay the progression of nephropathy. However, little data are
available on the beneﬁts of an MPD regimen in the management
of diabetic nephropathy in the older population. Our data are in
agreement with a previous large study that demonstrated
similar positive effects of dietary protein restriction [20]. Simi-
larly, results from another study reported the beneﬁcial effects of
a very-low-protein diet and a low-protein diet, both supple-
mented with ketoanalog [21]. However, in a recent study with
patients who had diabetic nephropathy, it was reported that
dietary protein restriction was neither feasible nor efﬁcacious.
That study also reported that the prescribed protein intake in the
low-protein diet group resulted in a daily mean protein intake of
about 1 g/kg, which was not statistically different from the
normal protein diet group. Thus, the non-adherence to the pre-
scribed dietary protein restriction may have underestimated its
beneﬁcial effects in this study [7]. Adherence to dietary protein
Fig. 2. Changes in C-reactive protein (CRP), interleukin-6 (IL-6) and urinary 8-
epiprostaglandin (Epi-PG)F2a in older patients with diabetes as the mean value
at baseline (T0) and the mean value every 3 mo during the treatment follow-up
(T36) in normal protein diet (NPD) (black) and moderate protein diet (MPD)
(white) groups. Values are mean  SEM. *P < 0.05 versus NPD.
Fig. 3. Relationship between the urinary 8-epiprostaglandin (epi-PG)F2a and
protein intake in the moderate protein diet (MPD) group (r ¼ 0.70, P < 0.01).
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in part, the different results observed in the long term.
We do not know the exact mechanisms by which the MPD
improved the renal failure in our patients. It is well known that
the persistence of heavy proteinuria is associated with an
intraglomerular hemodynamic change that induces glomerulo-
sclerosis and tubulointerstitial damage [22]. In this regard, we
reported a signiﬁcant reduction in proteinuria after an MPD
regimen. This antiproteinuric effect of dietary protein restriction
in diabetic nephropathy has been previously demonstrated [23]
and it seems to be independent from angiotensin-converting
enzyme inhibition therapy [24].
Additionally, the MPD group had a 10% of increase of unsat-
urated fat portion. Thus, it cannot be excluded that this may have
contributed at least in part to a lower inﬂammation low-grade
observed in this group. In fact, it has been reported that the
unsaturated lipids may have been linked to anti-inﬂammatorystatus [11]. It is also possible that the reduced inﬂammation
observed in the present study, after an MPD diet, is associated
with lower proteinuria that in turn could positively affect the
renal failure. In this regard, it recently has been reported that
moderate protein restriction improves oxidative stress, inﬂam-
mation, and proteinuria in the remnant kidney model [11].
Furthermore, it has been reported that treatment with dietary
protein restriction has an antioxidant effect both in humans and
animals with CKD [10,25,26]. These data may help explain the
mechanisms that underline the beneﬁt of dietary protein re-
striction on decline of renal function. Thus, it is possible that an
MPD regimen in our patients could suppress oxidative stress
and inﬂammation with a consequent reduction in proteinuria.
However, long-term dietary protein restriction may expose older
individuals to inadequate protein-energy and micronutrient in-
takes, which may cause deterioration in nutritional status, with
the developing of sarcopenia. Following anMPD 6 d/wk regimen,
we did not observe changes in FFM. This observation is in
agreement with previous data that reported the metabolic
changes induced by a reduced protein intake associated with a
decrease in protein oxidation and breakdown. This suggested an
adaptive response to dietary protein restriction, which probably
prevents patients with diabetes from developing protein
malnutrition [27]. Additionally, other studies have reported that
an MPD (providing sufﬁcient intake of calories and high bio-
logical value of protein) does not lead to malnutrition and
ameliorates metabolic acidosis [2]. However, the frustration of
further oral needs observed during dietary protein restriction
frequently leads to chronic depression, withdrawal, and poor
quality of life [28]. In this regard, we demonstrated that for older
individuals with T2DM, following dietary protein restriction for
only 6 d/wk reduces the risk for developing depressive symp-
toms without worsening health-related quality of life [8]. We
also observed that an MPD did not affect glycemia control in
these patients. Moreover, these data are in agreement with a
previous observation, which reported no changes in glucose
metabolism after dietary protein restriction in both animals and
humans [29–31].Conclusions
The present ﬁndings suggest that, in older individuals with
T2DM, an MPD restriction (providing about 0.7 g/kg per day, 6 d/
wk) may be useful in the management of diabetic nephropathy.
In fact, the MPD induced a signiﬁcant reduction in decline of
renal function, proteinuria, low-grade inﬂammation, and oxida-
tive stress. Additionally, these results were not associated with
M. Giordano et al. / Nutrition 30 (2014) 1045–1049 1049changes in FFM or glycemic control. A limitation of the present
study is represented by the sample size and larger, future studies
are needed to conﬁrm the present ﬁndings.
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